Introduction
============

Prostate cancer (PCa) is the most common malignancy in western males.[@b1-cmar-10-3125] It is estimated that 164,690 new PCa cases and 29,430 PCa-related deaths will occur in 2018 in USA.[@b1-cmar-10-3125] So far, prostate-specific antigen (PSA) has been mostly used for early detection and recurrence evaluation as a biomarker. Gleason score is a classical prognostic factor but not sufficient to portray the complexity of clinical prognosis.[@b2-cmar-10-3125] The heterogeneous genomic property of PCa can lead to the difficulty in survival prognosis and therapy monitoring. Therefore, there is an urgent need for novel effective parameters to predict outcomes for treatment decision. Recently, a number of biomarkers about PCa have been investigated and established in patient cohort studies.[@b3-cmar-10-3125]--[@b6-cmar-10-3125] In comparison with cancer tissues, serum is an ideal source of biomarkers because of the convenience in routine clinical measurement.[@b7-cmar-10-3125] Scientists have been trying for decades to seek the biomarkers among the different kinds of molecules such as proteins, noncoding RNAs, and chemical compounds.[@b8-cmar-10-3125] Interestingly, we notice that alkaline phosphatase (ALP), a classical parameter, also has a great potential in the prognosis of PCa.

The enzyme ALP can physiologically dephosphorylate compounds under alkaline pH environment.[@b9-cmar-10-3125] Serum ALP level is a widely used parameter for liver disease, bone disease burden, and treatment effects.[@b10-cmar-10-3125] It is acknowledged that the elevation in ALP level is positively related to the rise of bone activity like osteosarcoma.[@b11-cmar-10-3125] Therefore, we speculate that bone metastatic cancer may also lead to the rising of serum ALP, given that bone is the most common metastatic site of PCa. Over 85% patients died from bone metastasis among PCa-related deaths.[@b12-cmar-10-3125] So, can we identify the relationship between ALP and different survival outcomes in patients with PCa?

Up to now, the prognostic performance of ALP in patients with PCa has been discussed in many studies; however, these studies have yielded some conflicting conclusions. The aim of this study was to quantitatively and comprehensively derive a more precise prognostic estimation of ALP in patients with PCa by a meta-analysis.

Methods
=======

Search strategy
---------------

This meta-analysis adhered to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).[@b13-cmar-10-3125] A comprehensive literature search in the PubMed, Embase, and Web of Science was conducted from the databases onset to February 5, 2018. The key words were as follows: ("prostate neoplasms\[MeSH\]" OR "prostate cancer") AND "alkaline phosphatase" or "ALP" AND ("prognosis\[MeSH\]" OR "survival" OR "outcome"). The language of studies was not restricted. Additional relevant publications were also manually searched based on the reference lists.

Study selection
---------------

### Inclusion and exclusion criteria

Studies were included only if they met the following criteria: 1) clinical cohort/trial evaluated the prognostic ability of ALP in PCa; 2) studies compared ALP with other prognostic models and reported survival outcomes such as overall survival (OS), progression-free survival (PFS), and cancer-specific survival (CSS); 3) reported original HR with 95% CI or the HR could be calculated from sufficient data; 4) articles with the most complete information if there were several studies among overlapping cohorts or time periods.

The exclusion criteria were 1) duplicate publications; 2) studies based on less than 20 patients; 3) laboratory studies, animal studies, letters, or review articles.

Assessment of study quality
---------------------------

Two investigators (DL and XH) independently reviewed all the relevant articles, then evaluated the methodological quality of observational studies using Newcastle--Ottawa Quality Assessment Scale (NOS) assessment tool, including selection, comparability, and outcomes.[@b14-cmar-10-3125] The Jadad composite scale was utilized to assess randomized controlled trials (RCTs).[@b15-cmar-10-3125] The NOS score ≥7 or Jadad score ≥4 indicated high quality. Disagreements in data collection and quality assessment were resolved through consensus by involving a third author (HL).

Data extraction
---------------

The baseline and outcome data were obtained from each study: first author's surname, year of publication, study design, country, sample size, age, PSA level, cutoff value, follow-up time, outcomes, and HRs with 95% CI. If the HRs of both univariate and multivariate analysis were available, only the latter was used.

Statistical analysis
--------------------

HRs with 95% CI from all eligible studies were pooled via a meta-analysis to access the strength of ALP to survival endpoints. The Cochran *Q* test was used to determine the heterogeneity among studies. A *P* value \<0.10 indicated heterogeneity. The inconsistency (*I*^2^) was also calculated to evaluate heterogeneity. An *I*^2^ value \>50% indicated the presence of statistical heterogeneity. The random-effect model (DerSimonian and Laird method) was used to calculate pooled results when there was heterogeneity among included studies; otherwise, the fixed-effect model was used. To seek deeper relationship between ALP and OS, we conducted subgroup analyses on study type, cutoff value, sample size, and region of study. Furthermore, to test the reliability of the results, sensitivity analysis was conducted by removing each single study in turn. Begg's test with funnel plots was used to measure publication bias. The *P* value \>0.05 indicated no potential publication bias. The Stata 12.0 software (StataCorp, College Station, TX, USA) was used to perform all the statistical analyses. A two-sided *P* value \<0.05 was considered as statistically significant.

Results
=======

Studies selection and evaluation
--------------------------------

The flowchart of articles searching process is shown in [Figure 1](#f1-cmar-10-3125){ref-type="fig"}. A total of 1,107 relevant citations were initially retrieved by the search strategy as described above in PubMed, Embase, and Web of Science. Seven hundred forty duplicate articles were removed. Among the remaining 367 articles, 286 were further excluded for unrelated information and not clinical research articles. Eighty-one potential articles were screened carefully, 27 articles were ruled out because of lack of essential data of survival outcome or overlapping cohorts. If there were multiple outcomes in the same article, we considered them as different studies. Finally, 63 studies from 54 articles[@b16-cmar-10-3125]--[@b69-cmar-10-3125] published between 1995 and 2017 encompassing 16,135 patients were included in the meta-analysis, with the sample size ranging from 30 to 1,183 patients ([Table 1](#t1-cmar-10-3125){ref-type="table"}). The characteristics of the included studies are summarized in [Table 1](#t1-cmar-10-3125){ref-type="table"}. The median length of follow-up varied from 8.3 to 63.4 months. Prognostic outcomes were quantitatively synthesized, including OS, CSS, and PFS. A total of 36 observational studies and five RCTs had available data for the OS analysis, while seven studies reported HRs for CSS, and nine studies reported HRs for PFS. The quality assessment results of the 54 eligible articles shown in [Table S1](https://pan.baidu.com/s/1v8S90JdMxA8WzlzOy-cy3A) revealing the NOS score were equal or greater than 6 in all 48 observational studies and the Jadad score was over 4 in all six RCTs.

Overall analysis
----------------

### Meta-analysis on OS

There were 33 observational studies presenting the data of ALP and OS. The random effects model was used to analyze the relationship between them. The pooled HR was 1.74 (95% CI: 1.47--2.06, [Figure 2A](#f2-cmar-10-3125){ref-type="fig"}) with significant heterogeneity between studies (*I*^2^=96.1%, *P*\<0.001), which demonstrated a significant relationship between ALP and OS. However, the pooled HR was 1.15 (95% CI: 1.02--1.30, [Figure 2B](#f2-cmar-10-3125){ref-type="fig"}), which demonstrates a significant relationship among five RCTs. There were three studies comparing the decrease in serum ALP level and OS, whose pooled HR was 0.56 (95% CI: 0.42--0.75, [Figure 3A](#f3-cmar-10-3125){ref-type="fig"}). Besides, five studies investigated the relationship between bone-specific ALP (BAP) and OS in patients with PCa. The pooled HR for BAP and OS is 1.65 (95% CI: 1.41--1.92, [Figure 3B](#f3-cmar-10-3125){ref-type="fig"}).

### Meta-analysis on CSS

Seven studies provided sufficient data on ALP and CSS outcome. The pooled HR was 1.002 (95% CI: 0.998--1.005) via a random effects model, and the potential heterogeneity among studies was observed (*I*^2^=75.4%, *P*\<0.001, [Figure 4A](#f4-cmar-10-3125){ref-type="fig"}).

Meta-analysis on PFS
--------------------

Nine studies reported the data concerning the association between ALP and PFS. Meta-analysis adopting the random effects model revealed that elevated ALP was significantly associated with shorter PFS (HR=1.60, 95% CI: 1.13--2.26) with potential heterogeneity (*I*^2^=82.1%, *P*\<0.001, [Figure 4B](#f4-cmar-10-3125){ref-type="fig"}).

### Subgroup analyses

Moreover, we conducted a subgroup meta-analysis on different study designs. Although the main results were not affected by different study design, heterogeneity still existed in both prospective cohorts (HR=1.76, 95% CI: 1.42--2.19, Figure S1A) and retrospective studies (HR=1.58, 95% CI: 1.24--2.00, Figure S1B). In epidemiological studies, ethnicity difference was usually recognized as a critical source of bias. Notably, we also found the elevated serum ALP was significantly associated with poor OS among the studies in Asia (Figure S1C), Europe (Figure S1D), and North America (Figure S1E). Furthermore, we performed subgroup analysis in different cutoff values (Figure S1F, G) and sample sizes (Figure S1H, I). To sum up, the pooled HRs indicated that higher ALP was significantly associated with poorer OS in all subgroups of patients with PCa ([Table 2](#t2-cmar-10-3125){ref-type="table"}).

### Sensitivity analysis

The sensitivity analysis was performed by the sequential deletion of any individual article to measure the effects of each individual study. The results showed that the overall HRs were not significantly influenced by individual study, as shown in [Figure 5](#f5-cmar-10-3125){ref-type="fig"}, indicating the robustness of the results in our meta-analysis.

Assessment of publication bias
------------------------------

Begg's test was performed to evaluate the publication bias of the inclusion studies ([Figure 6](#f6-cmar-10-3125){ref-type="fig"}). The *P*-values of Begg's test for OS (observational studies and RCTs) were 0.747 and 0.086, respectively, indicating that there was no significant publication bias.

Discussion
==========

Serum ALP level is a simple and rapid laboratory test in routine clinical practice. An ideal prognostic biomarker can be used to determine prognosis, monitor response to therapy, and postoperative surveillance.[@b70-cmar-10-3125] The high ALP level has been reported related to the poor survival in colorectal cancer.[@b71-cmar-10-3125] The elevation of ALP is also an independent risk factor in the bone metastasis of gastric cancer and bladder cancer.[@b72-cmar-10-3125],[@b73-cmar-10-3125] However, the underlying mechanisms of ALP in patients with PCa remain unclear. A possible explanation is that when the PCa starts metastasis, ALP reflects bone turnover, osteoblast activity, and the osteoid formation in adjacent bone tissues.[@b11-cmar-10-3125] Thus, ALP may be an indicator of bone metastatic tumor load.

In this meta-analysis, based on the existing data from 63 included studies, the pooled results indicated that high baseline ALP was associated with obviously poor OS and PFS (HR=1.60, 95% CI: 1.13--2.26) in patients with PCa. As presented in [Table 1](#t1-cmar-10-3125){ref-type="table"}, most included studies used multivariate cox model to explore ALP and survival. After being adjusted for other factors such as tumor stage/grade, PSA, Gleason score, hemoglobin, and metastasis, the original results of ALP were objective and reliable. The meta-analysis on both observational studies (HR=1.74, 95% CI: 1.47--2.06) and RCTs (HR=1.15, 95% CI: 1.02--1.30) reached the consistent conclusions about ALP and OS. In addition, high serum BAP was also significantly related to poor OS (HR=1.76, 95% CI: 1.42--2.15). However, our result revealed that there was no association between ALP and CSS in patients with PCa (HR=1.002, 95% CI: 0.998--1.005). We hypothesize that ALP is more sensitive in reflecting bone metastasis, so, high serum ALP is significantly associated with PFS of PCa. PCa patients with bone metastasis and other underlying diseases may lead to poorer OS. Whereas the seven studies about CSS ([Figure 4A](#f4-cmar-10-3125){ref-type="fig"}) were all retrospective in the study design. The sample size was also relatively smaller for CSS than OS. Thus, we should carefully interpret the result of ALP and CSS. The results of subgroup analyses on different study types, regions, cutoff values, and sample sizes were all in accordance with the main findings. The sensitivity analysis and publication bias tests' outcomes also supported our results. Therefore, we may recommend ALP as a valuable prognostic marker for PCa treatment decision and adjustment. Compared with the positron emission tomography-computed tomography, ALP combined with bone scintigraphy may also be useful to assess the metastatic burden and survival possibility of PCa with a remarkably less expensive cost.

To our knowledge, this is the first meta-analysis on ALP and the prognosis of PCa. However, there are still a couple of limitations to be stated. First, although the language was not restricted during the searching process, all the included studies were in English, which might lead to language bias. Second, although sensitivity analysis supported the stability of our results, the findings should be cautiously interpreted. Heterogeneity among studies was found in overall and subgroup analyses. It was probably owing to multivariate factors in some included studies. Third, the data of ALP on other prognostic clinical parameters such as metastasis and all-cause mortality are lacking at present. Meanwhile, the retrospective design in 23 included studies ([Table 1](#t1-cmar-10-3125){ref-type="table"}) may cause potential recall bias. Thus, more large-scale prospective studies are warranted to testify the prognostic ability of ALP in PCa in the future. Moreover, BAP will also be a potential prognostic marker in PCa, which needs verification as well.

Conclusion
==========

In spite of the limitations mentioned above, the results of this study present the conclusion that high serum ALP is significantly associated with poor OS and PFS of PCa, but there is no obvious relation between ALP and CSS. ALP level is an efficient and convenient biomarker for PCa prognosis.
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![Forest plot of pooled HR and 95% CI of high ALP and OS prognosis.\
**Notes:** (**A**) Observational cohorts; (**B**) RCTs.\
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![Sensitivity analyses of high ALP and OS prognosis.\
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![Funnel plots of Begg's test of high ALP and OS prognosis.\
**Notes:** (**A**) Observational cohorts; (**B**) RCTs.\
**Abbreviations:** ALP, alkane phosphatase; OS, overall survival; RCT, randomized controlled trial.](cmar-10-3125Fig6){#f6-cmar-10-3125}

###### 

Baseline characteristics of included studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID                                     Country           Duration     Type   Sample size   Median age (years)   Median serum PSA (ng/mL)   Treatment                                                           Median follow-up (months)   Cutoff value (U/L)   HR       95% CI          Outcome   Multivariate analysis   Study quality (NOS score)
  -------------------------------------------- ----------------- ------------ ------ ------------- -------------------- -------------------------- ------------------------------------------------------------------- --------------------------- -------------------- -------- --------------- --------- ----------------------- ---------------------------
  Halabi et al 2013[@b16-cmar-10-3125]         USA               2007--2008   RCT    488           70 (63--75)          118 (40.3--370.2)          Docetaxel                                                           15                          NR                   1.02     0.96--1.07      OS        Yes                     7 (Jadad)

  Goldkorn et al 2014[@b17-cmar-10-3125]       USA               NR           RCT    470           69 (63--76)          68 (13--355)               Docetaxel                                                           24                          NR                   1.06     0.88--1.27      OS        Yes                     8 (Jadad)

  Schellhammer et al 2013[@b18-cmar-10-3125]   USA               2003--2009   RCT    512           71                   50.1                       Sipuleucel-T                                                        51.7                        131                  1.25     1.035--1.510    OS        Yes                     7 (Jadad)

  Humphrey et al 2006[@b19-cmar-10-3125]       USA               1996--1998   RCT    390           70 (64--75)          129 (50--339)              Suramin                                                             35                          170                  1.713    1.204--2.437    OS        Yes                     8 (Jadad)

  Halabi et al 2014[@b20-cmar-10-3125]         USA               NR           RCT    705           69                   79                         Docetaxel                                                           24                          NR                   1.16     1.00--1.30      OS        Yes                     8 (Jadad)

  Qu et al 2013[@b21-cmar-10-3125]             China             2005--2011   Re     115           68 (51--82)          90.5 (0.1--4,066)          Docetaxel                                                           40                          110                  1.934    1.112--3.363    OS        Yes                     7

  Mikah et al 2016[@b22-cmar-10-3125]          Germany           2009--2014   Re     84            69 (62.3--76)        174 (55--500)              Abiraterone                                                         14                          NR                   1.4      0.8--2.5        OS        No                      6

  Klaff et al 2016[@b23-cmar-10-3125]          Sweden            1992--1997   Pro    319           69                   233                        Hormonal therapy                                                    75.6                        NR                   1.16     0.76--1.75      OS        Yes                     7

  483                                          71                                                                       1.29                       1.02--1.63                                                          OS                          Yes                  7                                                          

  Miyamoto et al 2012[@b24-cmar-10-3125]       Japan             1992--2002   Pro    94            72.5 (47--90)        1,015.6 (8.5--18,948)      Hormonal therapy                                                    38.8                        440                  2.16     1.01--4.62      OS        Yes                     7

  Kita et al 2013[@b25-cmar-10-3125]           Japan             2005--2008   Re     57            71 (57--80)          51.3 (0.03--1,450)         Docetaxel                                                           20.5                        260                  2.39     1.12--5.10      OS        Yes                     7

  Bilen et al 2017[@b26-cmar-10-3125]          USA               2010--2012   Re     48            67 (51--84)          8.9 (2--477)               Sipuleucel-T                                                        28                          90                   8.7      1.7--46         OS        Yes                     7

  Omlin et al 2013[@b27-cmar-10-3125]          UK                2003--2011   Re     183           62 (41.8--77.3)      120 (0.97--11,343)         Postchemotherapy                                                    40                          NR                   1.29     1.02--1.64      OS        Yes                     7

  Nakashima et al 2000[@b28-cmar-10-3125]      Japan             NR           Pro    114           73                   NR                         Hormonal therapy                                                    40                          620                  1.28     0.608--2.695    OS        Yes                     6

  Templeton et al 2014[@b29-cmar-10-3125]      UK                2001--2011   Pro    357           71 (44--90)          162 (56--496)              Docetaxel                                                           18                          300                  1.58     1.01--2.45      OS        Yes                     7

  van Soest et al 2015[@b30-cmar-10-3125]      the Netherlands   2011--2014   Pro    114           68 (49--83)          182 (12.5--5,000)          Cabazitaxel                                                         24                          125                  1.65     1.06--2.57      OS        Yes                     7

  Sonpavde et al 2014[@b31-cmar-10-3125]       USA               2008--2010   Pro    873           68 (39--90)          130 (0.1--5,927)           Sunitinib                                                           15                          NR                   1.13     0.99--1.28      OS        Yes                     7

  Halabi et al 2003[@b32-cmar-10-3125]         USA               1992--1998   Pro    760           71                   126                        Mitoxantrone                                                        37                          172                  1.23     1.12--1.36      OS        Yes                     7

  Shiota et al 2014[@b33-cmar-10-3125]         Japan             2008--2013   Re     97            71 (51--85)          136.9 (3.1--10,860)        Docetaxel                                                           25                          360                  10.26    2.04--39.74     OS        Yes                     7

  Oh et al 2017[@b34-cmar-10-3125]             USA               2011--2014   Re     629           72                   310                        Cabazitaxel                                                         NR                          NR                   0.93     0.66--1.32      OS        Yes                     7

  Brasso et al 2006[@b35-cmar-10-3125]         Denmark           1993--1996   Pro    153           72 (54--89)          270 (10--7,730)            Hormonal therapy                                                    58                          275/BAP              1.7      1.4--2.1        OS        No                      6

  Chi et al 2016[@b36-cmar-10-3125]            Canada            2008--2009   Pro    762           69 (42--95)          128.8 (0.4--9,253.0)       Abiraterone                                                         30                          160                  2.02     1.69--2.41      OS        No                      7

  Nozawa et al 2015[@b37-cmar-10-3125]         Japan             2008--2010   Pro    52            72 (55--86)          249.4                      Bicalutamide or hormonal therapy                                    26                          300                  12.7     8.6--15.4       OS        No                      6

  Pienta et al 1997[@b38-cmar-10-3125]         USA               1993--1996   Pro    62            67 (47--80)          378 (0.7--2,007)           Estramustine                                                        13                          115                  0.878    0.62--1.280     OS        No                      6

  Reynard et al 1995[@b39-cmar-10-3125]        UK                1986--1993   Pro    85            71 (47--89)          NR                         Acetate                                                             30                          NR                   3.1      1.2--8.2        OS        Yes                     6

  Thatai et al 2004[@b40-cmar-10-3125]         USA               1991--2001   Pro    145           70 (52--82)          NR                         Chemotherapy                                                        10.5                        185                  1        0.6--1.4        PFS       No                      6

  Vesalainen et al 1995[@b41-cmar-10-3125]     Finland           1971--1992   Pro    188           71.5 (39.9--92)      NR                         Hormonal therapy                                                    36                          275                  1.008    1.002--1.011    OS        Yes                     6

  Etchebehere et al 2016[@b42-cmar-10-3125]    USA               2013--2015   Pro    110           70 (43--89)          37 (0.4--2,433)            Radium 233                                                          8.3                         146                  2.02     1.31--3.12      PFS       No                      7

  George et al 2001[@b43-cmar-10-3125]         USA               1996--1998   Pro    197           68 (62--75)          150 (48--418)              Chemotherapy                                                        14                          170                  1.6      1.05--2.14      OS        Yes                     7

  Buttigliero et al 2017[@b44-cmar-10-3125]    Italy             2004--2016   Re     71            68 (48--85)          47 (0.2--3,310)            Docetaxel                                                           31.7                        113                  0.71     0.37--1.39      PFS       Yes                     7

  Shigeta et al 2016[@b45-cmar-10-3125]        Japan             2007--2014   Re     106           73 (52--95)          31.7 (0.3--751.45)         Docetaxel                                                           36                          284                  1.651    1.04--2.621     PFS       Yes                     7

  Wyatt et al 2004[@b46-cmar-10-3125]          USA               1988--1995   Re     380           65.1                 NR                         Chemotherapy                                                        13.9                        NR                   1.11     0.95--1.34      OS        Yes                     7

  Ramankulov et al 2007[@b47-cmar-10-3125]     Germany           NR           Pro    90            64                   25.4                       Hormonal therapy                                                    40                          205/BAP              2.54     0.42--15.3      OS        Yes                     7

  Sonpavde et al 2012[@b48-cmar-10-3125]       Canada            2000--2002   Pro    601           68 (36--92)          144 (0.06--40,740)         Docetaxel                                                           36                          120                  1.64     1.28--2.10      OS        No                      6

  Halabi et al 2004[@b49-cmar-10-3125]         USA               1992--2002   Pro    1,183         71 (65--76)          106 (37--310)              Androgen deprivation therapy and antiandrogen withdrawal            14                          NR                   1.29     1.18--1.40      OS        Yes                     7

  Oh et al 2011[@b50-cmar-10-3125]             USA               1998--2006   Pro    302           62                   22.6 (5.2--95.1)           Orchiectomy                                                         79.2                        102                  1.72     1.17--2.52      OS        Yes                     7

  Izumi et al 2012[@b51-cmar-10-3125]          Japanese          2006--2010   Pro    30            65.5 (46--83)        200 (6--4,370)             Zoledronic acid                                                     17 (4--49)                  47/BAP               6.391    0.660--61.89    OS        Yes                     7

  Hammerich et al 2017[@b52-cmar-10-3125]      USA               1989--2010   Re     89            62.4 (6.7)           6.7 (0.8--53.2)            Androgen deprivation therapy                                        63.4 (16.7--186)            NR                   4.47     1.56--12.76     OS        Yes                     7

  Cook et al 2006[@b53-cmar-10-3125]           USA               1998--2001   RCT    278           71.7 (7.9)           282 (839)                  Prior cytotoxic chemotherapy, radiation therapy                     24                          267.5/BAP            1.49     1.17--1.90      OS        Yes                     8 (Jadad)

  Park et al 2012[@b54-cmar-10-3125]           Korea             2003--2009   Re     55            72.5±7.6             209.2±424.5                Docetaxel                                                           32.2±18.3                   NR                   14.112   4.235--75.045   CSS       Yes                     7

  Yamada et al 2010[@b55-cmar-10-3125]         Japan             1998--2006   Re     454           74                   268.7                      Endocrine therapy                                                   43                          NR                   1.829    0.881--3.798    CSS       Yes                     7

  Kamiya et al 2010[@b56-cmar-10-3125]         Japan             2002--2008   Re     58            69±8.2               1,402.4±2,055.3            NR                                                                  35.0±24.6                   683.4                5.55     0.919--33.513   CSS       Yes                     6

  Mohammed et al 2015[@b57-cmar-10-3125]       Saudi Arabia      2011--2015   Re     71            72±8.7               54 (0.1--16,430)           NR                                                                  14.4 (0.1--44.1)            NR                   1.001    1.000--1.002    CSS       Yes                     6

  Akimoto et al 1997[@b58-cmar-10-3125]        Japan             1979--1992   Re     56            71.8                 NR                         Endocrine therapy                                                   NR                          206                  1.533    0.747--3.144    CSS       Yes                     7

  Koo et al 2015[@b59-cmar-10-3125]            Korea             2002--2012   Re     248           NR                   NR                         NR                                                                  39.9                        200                  1.002    1.001--1.003    CSS       Yes                     6

  Kato et al 2016[@b60-cmar-10-3125]           Japan             2002--2012   Re     181           73                   328                        Androgen deprivation therapy                                        38                          398                  1.42\    0.88--2.30\     CSS\      Yes                     6
                                                                                                                                                                                                                                                                        1.57\    0.97--2.54\     OS\                               
                                                                                                                                                                                                                                                                        1.16     0.79--1.71      PFS                               

  D'Amico et al 2005[@b61-cmar-10-3125]        USA               1991--2001   Pro    281           72                   NR                         Taxotere, thalidomide, atrasentan, ketoconazole, and alendronate.   16.8                        NR                   1        0.8--1.2        OS        Yes                     8

  Bando et al 2017[@b62-cmar-10-3125]          Japan             2014--2016   Re     66            NR                   NR                         Cabazitaxel and docetaxel                                           10.3                        300                  1.73     0.80--3.85      PFS       Yes                     7

  Pelger et al 1996[@b63-cmar-10-3125]         the Netherlands   NR           Re     112           73                   NR                         Orchiectomy                                                         22                          200                  3.5      1.90--6.45      PFS       Yes                     7

  Han and Hong 2014[@b64-cmar-10-3125]         Korea             2002--2013   Re     61            69 (54--84)          299.0 (10.6--12,467.0)     Chemotherapy                                                        NR                          NR                   1.003    1.001--1.005    PFS       Yes                     7

  Goodman et al 2011[@b65-cmar-10-3125]        USA               2007--2009   Pro    33            66 (51--80)          57 (5.3--3,956)            Radical prostatectomy and radiation therapy                         11.2                        NR                   4.33     1.53--12.21     PFS       No                      6

  Matsuyama et al 2014[@b66-cmar-10-3125]      Japan             NR           Re     279           71 (48--91)          35.2 (0.05--3,134)         Docetaxel                                                           NR                          189                  2.95     1.15--8.85      OS        Yes                     7

  Fizazi et al 2015[@b67-cmar-10-3125]         USA               2006--2009   RCT    1,900         71 (38, 93)          59.5 (0.0--14,076.8)       Denosumab and zoledronic acid                                       20 (18--21)                 143/low              0.664    0.559--0.789    OS        Yes                     7 (Jadad)

  Rahbar et al 2018[@b68-cmar-10-3125]         Germany           2014--2016   Re     104           70 (64--76)          361 (80--755)              ^177^Lu-PSMA-617 RLT                                                14                          220/low              0.55     0.30--0.98      OS        Yes                     7

  Sartor et al 2017[@b69-cmar-10-3125]         UK                NR           Pro    400           NR                   NR                         Radium-223                                                          17.8                        NR/low               0.45     0.34--0.61      OS        Yes                     7
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** NR, not reported; HR, hazard ratio; Pro, prospective; Re, retrospective; ALP, alkane phosphatase; BAP, bone-specific ALP; PSA, prostate-specific antigen; OS, overall survival; PFS, progression-free survival; CSS, cancer-specific survival; RCT, randomized controlled trial.

###### 

Summary of the subgroup analysis results of ALP and OS prognosis for PCa

  Variable         Number of studies   Number of patients   Model   Outcome (OS)           Heterogeneity          
  ---------------- ------------------- -------------------- ------- ---------------------- --------------- ------ ---------
  Study type                                                                                                      
   Prospective     20                  7,082                R       1.764 (1.420--2.190)   \<0.001         97.5   \<0.001
   Retrospective   13                  2,319                R       1.581 (1.250--1.999)   \<0.001         65.6   \<0.001
  Region                                                                                                          
   Asia            9                   1,095                R       2.771 (1.347--5.703)   0.006           93.2   \<0.001
   Europe          9                   1,884                R       1.280 (1.069--1.532)   0.007           66.9   0.002
   North America   15                  6,422                R       1.637 (1.283--2.008)   \<0.001         95.3   \<0.001
  ALP cutoff                                                                                                      
   \>178           11                  1,670                R       2.734 (1.293--5.783)   0.009           98.4   \<0.001
   \<178           11                  2,453                R       1.578 (1.285--1.938)   \<0.001         77.5   \<0.001
  Sample size                                                                                                     
   \>180           17                  7,958                R       1.302 (1.161--1.459)   \<0.001         90.0   \<0.001
   \<180           16                  1,443                R       2.642 (1.565--4.460)   \<0.001         93.9   \<0.001

**Abbreviations:** ALP, alkaline phosphatase; OS, overall survival; PCa, prostate cancer; R, random-effects model.

[^1]: These authors contributed equally to this work
